Collegium Pharmaceutical Inc. (COLL) Trading 8.9% Higher
Shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) traded up 8.9% on Tuesday . The stock traded as high as $11.47 and last traded at $11.47, with a volume of 112,181 shares changing hands. The stock had previously closed at $10.53.
Several analysts have weighed in on the company. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 28th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $27.00 target price (up previously from $26.00) on shares of Collegium Pharmaceutical in a research note on Thursday, June 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price (up previously from $28.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. Finally, Gabelli began coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $27.60.
The stock has a 50-day moving average price of $10.57 and a 200 day moving average price of $14.52. The company’s market cap is $276.22 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/collegium-pharmaceutical-inc-coll-trading-8-9-higher.html
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.29. On average, equities analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.86) earnings per share for the current fiscal year.
In other Collegium Pharmaceutical news, Director John A. Fallon bought 2,375 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 12th. The shares were acquired at an average cost of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now directly owns 2,375 shares of the company’s stock, valued at $25,151.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 37.93% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. increased its position in Collegium Pharmaceutical by 155.8% in the first quarter. Franklin Resources Inc. now owns 829,599 shares of the specialty pharmaceutical company’s stock valued at $15,057,000 after buying an additional 505,299 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Collegium Pharmaceutical by 32.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 185,348 shares of the specialty pharmaceutical company’s stock valued at $3,364,000 after buying an additional 45,120 shares in the last quarter. M&T Bank Corp purchased a new position in Collegium Pharmaceutical during the first quarter valued at about $287,000. State Street Corp increased its position in Collegium Pharmaceutical by 45.7% in the first quarter. State Street Corp now owns 110,573 shares of the specialty pharmaceutical company’s stock valued at $2,009,000 after buying an additional 34,708 shares in the last quarter. Finally, Nicholas Investment Partners LP purchased a new position in Collegium Pharmaceutical during the first quarter valued at about $849,000. 62.13% of the stock is currently owned by institutional investors and hedge funds.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.